-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Clinical Fair Market Value: Why it's essential and what methodology to use
Jun 30, 2020
Fair Market Value (FMV) has become an industry standard in accordance with regulations and statutes such as the US Sunshine Act, False Claims Act, and Anti-Kickback Statute, as well as international transparency reporting and anti-corruption legislations. The key elements of a robust FMV practice continue, however, to evolve. As an industry, the Life Sciences has nearly uniformly adopted Healthcare Professional (HCP) FMV. Today, these evolutions and expansions have come to include Clinical FMV – the fair market valuation of clinical research budgets.
This article explores what is included in the umbrella term of “Clinical FMV,” why Clinical FMV is considered essential to a robust FMV Program, and what methodologies to consider in a proper valuation.
The funding of clinical research is a common tool to generate evidence in support of therapies and associated products to develop new indications or patient populations. This includes Pre-Clinical Research, Clinical Trials, Investigator Initiated studies, as other research-related activities such as protocol and publication development.
There are two main reasons why clinical research, a crucial mechanism of the life sciences industry, should be evaluated for FMV - compliance risk mitigation and commercial value.
Funding of certain clinical research arrangements can attract interest governing bodies like the Office of the Inspector General for violations of regulations such as the Anti-Kickback Statute. From a regulatory perspective, the evaluation of a clinical budget from a Fair Market Value perspective proves to governing bodies the organization’s proactive risk mitigation steps to remove any potential of overpayment, inducement, or kickback payments.
From a business point of view, installing a Clinical FMV arm to an existing FMV Program represents both significant cost and time savings. Evaluations of these budgets regularly discover formulaic errors or other oversights that may result in large-scale savings to the organization. Not only can Clinical FMV generate savings, but an established evaluation process can streamline the execution of contracts and launch of clinical research trials.
Organizationally, Clinical FMV can sit in a variety of divisions, including Compliance or Medical, or can be outsourced to a specialized group. Just as the existing approval process for studies must contain documented guidance and procedures, the fair market valuation process must be consistently applied, thoroughly documented, and pull from defensible sources and methodologies.
When assessing Clinical FMV, valuation experts utilize two core methodologies, commonly known as the market and cost-based approaches. As its name suggests, the market-based approach considers recent transactions of similar goods or services in order to arrive at FMV. While this approach is quick to implement, it comes with several caveats.
To make an accurate valuation using the market approach, the valuator needs to leverage a dataset with a robust sample size containing highly comparable transaction types. In the Clinical FMV marketplace, often entailing complex and unusual transactions, ample data is often not available. Secondly, because this approach relies on benchmarking from preexisting datapoints, pricing transparency can be elusive.
This can lead to the incorporation of cost drivers that may represent kickback risks or unnecessary costs to your organization.
In comparison, the cost-based approach relies on identifying each known cost driver within the item being evaluated in order to build an accurate Fair Market Valuation of the given budget line item. Understandably, this approach may require intricate operational knowledge and an upfront investment of time in order to identify all potential cost drivers – a task that some may not have the knowledge or time to properly execute.
Despite these barriers to entry, the cost-based approach maintains considerable merit in the world of valuation experts for the results are typically more accurate and tailored to the exact good or service being evaluated, stepping away from an approximated figure to a true valuation. Further, any given line item does not require a pre-existing dataset – a new valuation can be crafted and stand on its own. Eventually, in an environment where many Clinical FMV evaluations are applied, valuators will see line items repeat in new studies and the upfront investment in tailored valuations prove worthy.
When assessing the appropriateness of a market versus cost-based approach, there are some general guidelines that can be applied. A market approach should only be used when there is low compliance risk and a robust, accurate dataset available. In scenarios with unique or complex items being evaluated that entail higher compliance risk, the cost approach is the more accurate and fitting methodology.
As FMV continues to encompass more activities of life sciences companies, Clinical FMV is a crucial addition to your existing Compliance FMV Program. With the right process and methodology in place, it can reduce regulatory risks as well as expenditures. IQVIA Commercial Compliance assists companies in compliant and effective FMV programs. We welcome the opportunity to discuss your requirements. For more information, please email commercialcompliance@iqvia.com or visit our webpage.